Endothelial IGF‐1 receptor mediates crosstalk with the gut wall to regulate microbiota in obesity by Haywood, NJ et al.
Report
Endothelial IGF-1 receptor mediates crosstalk with
the gut wall to regulate microbiota in obesity
Natalie J Haywood1 , Cheukyau Luk1, Katherine I Bridge1, Michael Drozd1, Natallia Makava1,
Anna Skromna1, Amanda Maccannell1, Claire H Ozber1, Nele Warmke1, Chloe G Wilkinson1,
Nicole T Watt1 , Joanna Koch-Paszkowski1, Irvin Teh1, Jordan H Boyle2, Sean Smart3,
Jurgen E Schneider1, Nadira Y Yuldasheva1, Lee D Roberts1, David J Beech1, Piruthivi Sukumar1,
Stephen B Wheatcroft1, Richard M Cubbon1 & Mark T Kearney1,*
Abstract
Changes in composition of the intestinal microbiota are linked to
the development of obesity and can lead to endothelial cell (EC)
dysfunction. It is unknown whether EC can directly influence the
microbiota. Insulin-like growth factor-1 (IGF-1) and its receptor
(IGF-1R) are critical for coupling nutritional status and cellular
growth; IGF-1R is expressed in multiple cell types including EC. The
role of ECIGF-1R in the response to nutritional obesity is unex-
plored. To examine this, we use gene-modified mice with EC-speci-
fic overexpression of human IGF-1R (hIGFREO) and their wild-type
littermates. After high-fat feeding, hIGFREO weigh less, have
reduced adiposity and have improved glucose tolerance. hIGFREO
show an altered gene expression and altered microbial diversity in
the gut, including a relative increase in the beneficial genus Akker-
mansia. The depletion of gut microbiota with broad-spectrum
antibiotics induces a loss of the favourable metabolic differences
seen in hIGFREO mice. We show that IGF-1R facilitates crosstalk
between the EC and the gut wall; this crosstalk protects against
diet-induced obesity, as a result of an altered gut microbiota.
Keywords endothelium; IGF-1R; microbiota; obesity
Subject Categories Metabolism; Microbiology, Virology & Host Pathogen
Interaction; Signal Transduction
DOI 10.15252/embr.202050767 | Received 28 April 2020 | Revised 12 March
2021 | Accepted 22 March 2021
EMBO Reports (2021) 22: e50767
See also: Z Bouman Chen & N Kaur Malhi (May 2021)
Introduction
In the intestine are trillions of microorganisms which are collectively
described as the gut microbiota. The traditional dogma that the gut
microbiota is pathogenic has evolved with an appreciation of its
important role in the maintenance of human health (Lynch & Peder-
sen, 2016). Recent studies indicate that the gut microbiota is impor-
tant in the metabolic response to changes in dietary composition
(Backhed et al, 2004; Turnbaugh et al, 2006; Vrieze et al, 2012).
Obesity secondary to excess calorie intake is a major risk factor for
the development of a range of common disorders of human health
including the following: type 2 diabetes (Guariguata et al, 2013), fatty
liver (Yki-J€arvinen, 2014) and a number of cancers (Gallagher &
Leroith, 2015). While our understanding of the mechanisms underly-
ing the development and complications of obesity remains incom-
plete, a role for adverse remodelling of the gut microbiota has
recently emerged as an important factor in the unfavourable effects
of the disorder in a range of tissues and organs (Backhed et al, 2004;
Turnbaugh et al, 2006; Khan et al, 2016; Patterson et al, 2016;
Castaner et al, 2018) including the vascular endothelium (Koren
et al, 2011; Karlsson et al, 2012; Catry et al, 2018; Leslie & Annex,
2018; Amedei & Morbidelli, 2019). The endothelium, previously
thought to be an inert monolayer, has emerged as a complex para-
crine/autocrine organ, important in the regulation of a range of
homeostatic processes (Lee et al, 2007; Ding et al, 2010; Kivel€a et al,
2019; Tang et al, 2020). It is currently unknown whether the endothe-
lium can influence the composition of the intestinal microbiota.
The insulin-like growth factors (IGF-I and IGF-II) are evolution-
ally conserved peptide hormones that couple nutrient intake to
cellular growth (Jones & Clemmons, 1995). The effects of IGF-I are
predominantly mediated by the activation of its plasma membrane
receptor—IGF-1R (Adams et al, 2000). During calorie excess, the
expression of IGF-1R changes in a range of tissues, including the
endothelium, where we have shown it to decline (Mughal et al,
2019). The IGF-1R has also been shown to modulate the intestinal
barrier (Dong et al, 2014), and conversely, the microbiome has been
shown to modulate IGF-1R signalling in muscle (Schieber et al,
2015) and bone formation (Yan et al, 2016). Therefore, to explore
the effects of endothelial IGF-1R on metabolic responses to obesity
and the microbiome, we fed mice with endothelial cell
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overexpression of human IGF-1R (hIGFREO) (Imrie et al, 2012) an
obesogenic high-fat high-calorie diet. Feeding hIGFREO an obeso-
genic diet revealed a hitherto unrecognised mode of communication
between the endothelium and the gut wall leading to favourable
remodelling of the gut microbiota which protects against the devel-
opment of diet-induced obesity and its adverse metabolic sequelae.
Results and Discussion
Endothelial IGF-1R overexpression prevents high-fat
diet-associated weight gain
To explore the role of IGF-1R in the endothelium under circum-
stances recapitulating diet-induced obesity, we fed hIGFREO and
wild-type littermates (WT) a 60% high-fat diet (HFD) for 8 weeks
(Fig 1A). Endothelial overexpression of hIGF-1R was confirmed
using qPCR (Fig 1B); endothelial insulin receptor expression was
similar in hIGFREO and WT (Fig 1C); this expression pattern was
recapitulated at the protein level (Fig 1D and E). Protein markers of
vascular function (eNOS and AKT) in the aorta were unchanged
between the genotypes (Fig EV1A and B). On chow diet, hIGFREO
had similar weight to WT, as we have previously reported (Imrie
et al, 2012); however, on HFD, hIGFREO did not gain as much weight
as WT mice (Fig 1F). MRI was used to assess whole-body adiposity;
hIGFREO had significantly less subcutaneous and visceral adipose
tissue compared with WT on HFD (Fig 1G and H). Wet organ weight
confirmed that hIGFREO had smaller white epididymal adipose
depots than WT on HFD, with no difference in heart, spleen or liver
weight (Fig 1I). The IGF-1R is known to be an important regulator of
foetal and postnatal growth (Woods et al, 1996; Garcia et al, 2014;
Fujimoto et al, 2015; Juanes et al, 2015), and hIGFREO and WT mice
had similar body and femur length (Fig 1J), demonstrating that
endothelial IGF-1R overexpression did not cause growth retardation.
Overexpression of endothelial IGF-1R prevents obesity-associated
glucose intolerance
Chow-fed hIGFREO had similar glucose tolerance as WT (Fig EV1C–
E). However, when challenged by a HFD, hIGFREO had significantly
lower fasting blood glucose compared with WT (Fig 2A) and were
also protected from the glucose intolerance seen in WT (Fig 2B and
C). hIGFREO on HFD were also more insulin sensitive as shown
using the homeostatic model assessment of insulin resistance
(HOMA-IR) analysis (Fig 2D), which was associated with an increase
in the expression of AKT and phosphorylation of AKT at serine 437
in skeletal muscle of hIGFREO (Fig EV1F and G). hIGFREO and WT
had similar fasting plasma concentrations of IGF-I and insulin
(Fig 2E and F). HFD-fed hIGFREO handled olive oil gavage more
effectively over a 3-hr period postgavage with a significantly smaller
increment in plasma triglycerides than WT (Fig 2G and H).
Endothelial IGF-1R overexpression does not lead to changes in
activity, food intake or energy expenditure
To further probe the mechanisms underpinning the anti-obesity and
anti-diabetic effect of endothelial IGF-1R, metabolic cages were used
to perform measurement of multiple metabolic parameters.
◀ Figure 1. Endothelial IGF-1R overexpression prevents high-fat diet (HFD)-induced weight gain.
A Schematic representation of feeding time course.
B, C In primary endothelial cells isolated from human IGF-1 receptor endothelial overexpressing mice (hIGFREO) and wild-type littermates (WT), quantitative
polymerase chain reaction (qPCR) shows that hIGFREO have increased expression of human IGF-1R but similar levels of murine insulin receptor (IR) gene
expression as WT (n = 3–5 mice per group).
D, E In primary endothelial cells isolated from WT and hIGFREO, immunoblotting shows that hIGFREO have increased expression of IGF-1R but similar levels of IR
protein expression (n = 3–4 mice per group).
F Chow-fed hIGFREO had similar body mass to WT; however, hIGFREO did not gain as much weight as WT after 8 weeks of HFD (n = 6–10 mice per group).
G Representative images of difference in fat and water distribution shown by magnetic resonance (MR) imaging in hIGFREO and WT. Scale bar = 1 cm.
H Subcutaneous white adipose tissue (sWAT) and visceral white adipose tissue (vWAT) volumes were reduced in hIGFREO (n = 4 per genotype).
I hIGFREO had reduced white epididymal adipose depot weight compared with WT; there was no difference in heart, spleen or liver weight (n = 7–11 mice per
group).
J hIGFREO had similar whole-body and femur length as WT (n = 7–9 mice per group).
Data information: Data shown as mean  SEM, individual mice are shown as data points, P < 0.05 taken as being statistically significant using Student’s t-test and
denoted as * (** denotes P ≤ 0.01, ns denotes not significant).
Source data are available online for this figure.
▸Figure 2. Endothelial IGF-1R overexpression prevents high-fat diet (HFD)-induced glucose intolerance.A Human IGF-1R endothelial overexpressing mice (hIGFREO) had significantly lower fasting blood glucose compared with wild-type littermates (WT) after HFD
(n = 5–7 mice per group).
B, C hIGFREO had reduced glucose intolerance compared with WT (as measured by glucose tolerance test and area under the curve (AUC)) (n = 5–7 mice per group).
D hIGFREO had improved insulin sensitivity compared with WT as shown by lower HOMA-IR score (n = 9–10 mice per group).
E, F hIGFREO and WT had similar fasting plasma IGF-1 and insulin concentrations (n = 6–12 mice per group).
G, H Percentage change in plasma levels of triglycerides after an olive oil oral gavage was reduced over the 3-h period postgavage in hIGFREO compared with WT and
shown as area under the curve (n = 10–12 mice per group).
Data information: Data shown as mean  SEM and individual mice are shown as data points, P < 0.05 taken as being statistically significant using Student’s t-test and
denoted as * (** denotes P ≤ 0.01, ns denotes not significant).
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hIGFREO on HFD showed no difference in activity levels (Fig 3A),
food consumption (Fig 3B), oxygen consumption (Fig EV2A),
carbon dioxide production (Fig EV2B), energy expenditure (Fig 3C)
or respiratory exchange ratio (Fig EV2C) compared with WT on
HFD. IGF-1R are thought to contribute to temperature homeostasis
and may contribute to regulation of energy homeostasis during
calorie restriction (Cintron-colon et al, 2017). Going against this
possibility adipose tissue expression of browning markers (Fig 3D)
and body temperature (Fig 3E) were all unchanged in hIGFREO
compared to WT. Plasma leptin and adiponectin were also no dif-
ferent (Fig EV2D and E). There was also no difference in adipose
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adipose tissue vascularity (Fig EV3D and E) and adipose tissue
inflammatory markers, in hIGFREO and WT on HFD (Fig EV3F–I).
There was no difference in hepatic steatosis (Fig EV4A–H), pancre-
atic lipase or gene expression of cholesterol 7alpha-hydroxylase
(Cyp7a) and ATP Binding Cassette Subfamily B Member 11(Abcb11)
in liver when comparing hIGFREO to WT (Fig EV4I–K). There was
no difference in small intestine length (Fig 3F), villi histology
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Endothelial IGF-1R overexpression alters the gut microbiota and
augments the abundance of the beneficial genus Akkermansia
We then asked whether IGF-1R facilitated endothelial communica-
tion with the gut wall to influence the microbiota. Faith’s phyloge-
netic diversity (PD), a measure of faecal microbial diversity, was
significantly different in hIGFREO compared with WT after HFD
(Fig 4A and B). Chao-1 analysis, a complementary measure of faecal
microbial diversity and abundance, was also significantly different
(Fig 4C and D). To further investigate these changes to the micro-
biota and assess the contribution of each genus to the difference
between hIGFREO and WT, partial least squares discriminant analy-
sis (PLS-DA) modelling and the variable importance in projection
(VIP) score were performed. This demonstrated that hIGFREO mice
on HFD have increased abundance of Escherichia Shigella, Coriobac-
teriaceae UCG-002, Faecalibaculum, Peptococcus, Akkermansia and
Dehalobacerium. hIGFREO mice on a HFD are depleted in Enterococ-
cus, Barnesiella, Helicobacter, Streptococcs, Tyzzerella, Lach-
nospiraceae NK4A136 and Bilophila, as well as several genera from
the Ruminococcaceae family (Fig 4E and F).
Of particular relevance to our findings was the increase in relative
abundance of the genus Akkermansia (Derrien, 2004) seen in high-
fat-fed hIGFREO. Akkermansia is thought to have anti-obesity and
anti-diabetic effects in both humans and rodents (Everard et al, 2013;
Cani & de Vos, 2017; Plovier et al, 2017; Depommier et al, 2019).
Specifically, Akkermansia muciniphila reduces diet-induced weight
gain, fat mass development, fasting hyperglycaemia and improves
glucose tolerance without affecting food intake in mice (Everard
et al, 2013), the same phenotype observed in hIGFREO. Increased
levels of Akkermansia muciniphila are also associated with better
clinical outcomes, such as insulin sensitivity, after a calorie restricted
diet in overweight/obese adults (Dao et al, 2016). More recently, a
proof-of-concept clinical trial in obese humans demonstrated that
supplementation with Akkermansia muciniphila was a safe, well-
tolerated intervention which improved several metabolic parameters
(Depommier et al, 2019). However, it is also noteworthy that Bilo-
phila was depleted in high-fat-fed hIGFREO; Bilophila has previously
been shown to contribute to HFD-induced metabolic dysfunction
(Natividad et al, 2018). Dehalobacerium was enhanced in high-fat-
fed hIGFREO mice and has previously been shown to be protective
against atherosclerosis and reduced cholesterol (Chan et al, 2016). It
is difficult to speculate further about the contribution of these other
genera as little more is known about their role in obesity and meta-
bolic disease; further studies would be of interest. Interestingly, when
hIGFREO mice were unchallenged on a chow diet, there was no dif-
ference in microbial diversity compared with WT (Fig EV5D–G).
To dissect potential mechanisms underpinning the altered micro-
bial diversity, we examined the expression of genes known to
modulate the microbiota (Chang & Kao, 2019). We saw several
changes in gene expression in the gut wall (Fig EV5H–J), raising the
possibility that crosstalk between endothelial cells and the gut wall
can influence gene expression. It is well established that endothelial
cells can act in a paracrine/autocrine fashion (Lee et al, 2007; Ding
et al, 2010; Kivel€a et al, 2019) and equally well established that
enterocytes respond to microbial metabolites (Nuenen et al, 2005;
Garrett, 2020). To examine a role for secreted factors from endothe-
lial cells in the altered gene expression seen in hIGFREO small intes-
tine, we used primary endothelial cells from hIGFREO to condition
culture media to treat Caco-2 cells, as a model of the intestinal
epithelial barrier. Caco-2 cells treated with conditioned media from
hIGFREO showed a significant increase in regenerating islet-derived
III-c (REG3G) compared with WT gene expression (Fig EV5K).
REG3G belongs to the family of C-type lectins and is one of several
antimicrobial peptides produced by Paneth cells and enterocytes
(Chang & Kao, 2019; Shin & Seeley, 2019). REG3G destroys gram-
positive bacteria by binding to the peptidoglycan layer, exerting
bactericidal activity by oligomerising to form hexameric transmem-
brane pores (Shin & Seeley, 2019), thus providing one explanation
◀ Figure 3. Protection from high-fat diet (HFD)-induced weight gain in human IGF-1R endothelial overexpressing mice (hIGFREO) is not due to changes inactivity, food intake, energy expenditure, adipose browning or gut transit time.
A–C hIGFREO exhibit no difference in activity levels, food consumption or energy expenditure using indirect calorimeter assessment after HFD compared with wild-type
littermates (WT) after HFD. (n = 4 per genotype).
D Adipose expression of browning markers is also no different in white epididymal adipose tissue and brown adipose tissue compared with WT (n = 6 per genotype).
E Core body temperature is no different in hIGFREO compared with WT (n = 6–8 mice per group).
F, G Gut transit time is also unaltered in hIGFREO compared with WT as shown by no change in small intestine length (F) (n = 7–9 mice per group), or total gut transit
time after a carmine red gavage (G) (n = 12–13 mice per group).
Data information: The light/dark cycle for graphs A–C is shown as follows: light in yellow and dark in brown. Data shown as mean  SEM and individual mice are
shown as data points. For indirect calorimetry, ANOVA testing was performed using mass as a co-variant (ANCOVA testing) using calrapp.org. ns denotes not significant.
▸Figure 4. Endothelial IGF-1R overexpression alters the gut microbiota and augments the abundance of the beneficial genus Akkermansia.A, B Faith’s phylogenetic diversity (PD) was used to measure the faecal microbial diversity and demonstrates a significant difference between human IGF-1R endothelial
overexpressing mice (hIGFREO) mice and wild-type littermates (WT) mice after high-fat diet feeding (n = 4–5 mice per group).
C, D Chao-1 analysis was used to measure the faecal microbial diversity and abundance and demonstrates a significant difference between hIGFREO and WT (n = 4–5
mice per group).
E, F Partial least squares discriminant analysis (PLS-DA) model and used the variable importance in projection (VIP) score was used to assess the contribution of each
genus, shown as a scores plot in (E), and a loading plot of PLS-DA of genus abundances in (F). VIP score cut-off of 1 (n = 4–5 mice per group).
Data information: Data shown as mean  SEM and individual mice are shown as data points. Diversity analyses were run on the resulting OTU/feature.biom tables to
provide both phylogenetic and non-phylogenetic metrics of alpha and beta diversity. Additional data analysis (PLS-DA) and statistics were performed with R. P < 0.05
taken as being statistically significant using Student’s t-test and denoted as *.
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as to why hIGFREO display reduced microbiota diversity and possi-
bly providing an explanation as to why relative levels of Akkerman-
sia, a gram-negative bacteria, are enhanced. This raises the
intriguing possibility that endothelial cell IGF-1R could be a nutrient
sensor responding to nutritional cues to influence the architecture of
the intestinal microbiome (Bettedi & Foukas, 2017).
A
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Antibiotic administration in the setting of obesity prevents the
anti-obesity and anti-diabetic actions of endothelial IGF-1R
overexpression
To investigate the contribution of the altered microbiota to the anti-
obesity and anti-diabetic effects of endothelial IGF-1R overexpres-
sion, hIGFREO and WT were given broad-spectrum antibiotics in
their drinking water (Rodrigues et al, 2017) for the duration of HFD
(Fig 5A). The addition of antibiotic treatment alongside HFD abol-
ished the difference in weight gain seen between hIGFREO and WT
(Fig 5Bi). However, WT on HFD and antibiotic treatment did not
gain as much weight as WT on HFD alone. On chow diet hIGFREO
and WT did not tolerate prolonged antibiotic treatment and for
welfare reasons had to be culled, thus suggesting that the mice did
not completely tolerate antibiotic treatment. Nevertheless, both WT
and hIGFREO gained significantly more weight than mice on chow
diet (Fig 5Bii). Antibiotic treatment also prevented the difference in
glucose intolerance, seen between the genotypes when on HFD
alone (Fig 5C–E). Wet organ weights were comparable between
hIGFREO and WT (Fig 5F). Chao-1 analysis was no different
between hIGFREO and WT after HFD and antibiotic treatment
(Fig 5G). Alpha diversity in hIGFREO and WT on HFD treated with
antibiotics was also similar demonstrating no difference in microbial
diversity using a range of approaches (Fig 5H and Table EV1).
Taken together, these data confirm a causal role for the microbiota
in the favourable changes seen in hIGFREO.
Conclusion
To our knowledge, this is the first report to demonstrate communi-
cation between the endothelium and the gut wall, which in turn can
modulate the gut microbiota. We report a novel role for endothelial
cell IGF-1R in this crosstalk, which protects against diet-induced
obesity and its associated adverse metabolic sequelae, by potentially
remodelling the architecture of the microbiota.
Materials and Methods
Animal husbandry
hIGFREO mice with endothelial cell-specific overexpression of the
IGF-1 receptor (previously described Imrie et al, 2012) and their
wild-type control littermates (WT) were bred in house. Experiments
were carried out under the authority of UK Home Office project
licence P144DD0D6. Mice were group housed in cages of up to five,
which contained a mix of genotypes. Researchers were blinded to
genotype until the data analysis stage. Cages were maintained in
humidity and temperature-controlled conditions (humidity 55% at
22°C) with a 12-h light–dark cycle. All interventions were performed
within the light cycle. Only male mice were used for experimental
procedures to prevent variability associated with the oestrous cycle
on adiposity and metabolic readouts (Stubbins et al, 2012; Griffin
et al, 2016). Genotyping was carried out by Transnetyx commercial
genotyping using ear biopsies.
To induce obesity, mice received high-fat diet (HFD) ad libitum
from 8 weeks of age for a further 8 weeks (60% of energy from fat)
(F1850, Bioserve) with the following composition: protein 20.5, fat
36% and carbohydrate 36.2% (5.51 kcal/g).
Antibiotics were administered in a cocktail with the following
concentrations: ampicillin (1/gl), metronidazole (1/gl), neomycin
trisulfate (1/gl) and vancomycin (0.5/gl) in drinking water (Rodri-
gues et al, 2017), from the age of 8 weeks old for the duration of
high-fat feeding (further 8 weeks).
Metabolic phenotyping
Mice were fasted overnight prior to glucose tolerance or for 2hr
prior to insulin tolerance tests. Blood glucose was measured using a
handheld Glucose Meter (Accu-Chek Aviva). An intra-peritoneal
injection of glucose (1 mg/g) or recombinant human insulin
(Actrapid; Novo Nordisk) (0.75 IU/kg) was given and glucose
concentration measured at 30-min intervals for 2 h from the point
of glucose/insulin administration. Mice were not restrained between
measurements (Haywood et al, 2017).
Fasting plasma samples were collected from the lateral saphe-
nous vein (EDTA collection tubes Sarstedt 16.444). Samples were
then spun at 12,300 g for 10 min in a bench top centrifuge. Fasting
plasma insulin (90080, Crystal Chem), IGF-I (MG100, R and D
systems), leptin (EZML-82K, Merck Millipore) and adiponectin
(EZMADP-60K, Merck Millipore) were measured as per manufac-
turer’s instructions.
Core body temperature was measured using an Indus rectal
temperature probe (Vevo2100 (VisualSonics, FujiFilm).
After 8 weeks of HFD, metabolic parameters were measured by
indirect calorimetry using Comprehensive Lab Animal Monitoring
◀ Figure 5. Antibiotic administration in the setting of high-fat diet (HFD) eliminates the anti-obesity and anti-diabetic actions of endothelial IGF-1Roverexpression.
A Schematic representation of antibiotic dosing and feeding time course.
B (Bi), Human IGF-1R endothelial overexpressing mice (hIGFREO) had comparable weight gain as wild-type littermates (WT) after 8 weeks of HFD + antibiotics (ABs)
when compared to WT. (Bii), Both hIGFREO and WT gained significant weight compared with chow-fed mice (n = 7–9 mice per group).
C There was no difference in fasting blood glucose in hIGFREO compared with WT (n = 7–9 mice per group).
D, E There was no difference in hIGFREO and WT glucose tolerance (as measured by glucose tolerance test and area under the curve (AUC)) (n = 7–9 mice per group).
F Wet organ weights were similar in hIGFREO and WT (n = 7–9 mice per group).
G Chao-1 analysis was used to measure the faecal microbial diversity and abundance and demonstrates no difference between hIGFREO and WT after HFD +
antibiotic treatment (n = 3–5 mice per group).
H Alpha diversity P values using Kruskal–Wallis pairwise comparisons show there is no difference in microbial diversity.
Data information: Data shown as mean  SEM and individual mice are shown as data points, P < 0.05 taken as being statistically significant using Student’s t-test and
denoted as * or ** for P P < 0.01 and NS denotes not significant. Diversity analyses were run on the resulting OTU/feature.biom tables to provide both phylogenetic and
non-phylogenetic metrics of alpha and beta diversity. Additional data analysis (PLS-DA) and statistics were performed with R.
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Systems (CLAMS) (Columbus Instruments). In brief, mice were indi-
vidually housed for 5 days and measurement of oxygen consump-
tion, carbon dioxide production, food intake and locomotor activity
were continuously recorded. For each mouse, a full 24-h period,
taking into account sleep and wake cycles, was analysed after an
acclimatisation period (Roberts et al, 2014).
After 8 weeks of HFD (or at 8 weeks old for chow control mice),
all mice were sacrificed using terminal anaesthesia and organ
weights measured using a standard laboratory balance.
Lipid absorption
Mice were fasted overnight and blood samples collected from the
lateral saphenous vein (EDTA collection tubes Sarstedt 16.444).
Mice underwent oral gavage with 200 µl olive oil, and blood was
taken from the saphenous vein every hour for a further 3 h (Zhang
et al, 2018). Plasma triglycerides were measured using a commer-
cially available kit (ab65336, Abcam).
Intestinal transit time
Mice were fasted overnight before oral gavage with 300 µl of
Carmine solution (6% Carmine red (C1022, Sigma) in 0.5% methyl
cellulose (M7140, Sigma-Aldrich)). Mice were then individually
caged and monitored until the appearance of the first red faecal
pellet (Li et al, 2011).
Magnetic resonance imaging (MRI)
Anaesthesia was induced using 5% isoflurane in 100% oxygen and
then maintained using 1.5–3% isoflurane at 2 l/min oxygen flow.
Animals were positioned prone on a dedicated mouse cradle. Body
temperature was maintained with a custom resistive blanket placed
on the back of the animal. Cardiac and respiratory signals were
continuously monitored (BIOPAC Systems, Inc., Goleta, USA). Mice
were imaged on a 7T preclinical MRI scanner with a 660 mT/m
shielded gradient system and a quadrature-driven transmit/receive
volume coil with inner diameter of 72 mm (Bruker BioSpin MRI
GmbH, Ettlingen, Germany). A 2D cardiac-triggered and respiratory-
gated 3-point Dixon spoiled gradient-echo sequence was used:
TR = 5.65 ms, TE = 2.42/2.75/3.09 ms, Matrix = 256 × 128, field-
of-view = 80 × 30 mm, number of slices = 28 in sagittal orienta-
tion, slice thickness = 1 mm, number of signal averages = 8, total
scan time ~30 min. The data were analysed in MATLAB (Math-
Works, Natick, USA) using the hierarchical iterative decomposition
of water and fat with echo asymmetry and least squares estimation
(IDEAL) method(Tsao & Jiang, 2013). The proton density fat frac-
tion (PDFF, the amount of lipid signal over total signal) was used to
segment adipose tissue depots. Subcutaneous and visceral adipose
depots were segmented separately using Osirix Lite v11.0.2 (Bernex,
Switzerland) 2D threshold region growing algorithm tool with
segmentation parameters set to a lower threshold of 80% PDFF.
Gene expression
RNA was isolated from cells and tissue samples using the monarch
total RNA mini kit (NEB, T2010S). The concentration of RNA in
each sample (ng/µl) was measured using a NanoDrop. cDNA was
reverse transcribed (NEB, E3010S). Quantitative PCR (qPCR) was
performed using a Roche LightCycler 480 Instrument II, using SYBR
Green PCR Master Mix (Bio-Rad, 1725270) and relevant primers
(See Table 1). The “cycles to threshold” (cT) was measured for each
well, the average of triplicate readings for each sample taken,
normalised to GAPDH, and finally, the differential expression of
each gene was calculated for each sample.
Quantification of protein expression
Cells were lysed or tissue mechanically homogenised in lysis buffer
(Extraction buffer, FNN0011) and protein content quantified using a
BCA assay (Sigma-Aldrich, St. Louis, MO). Twenty micrograms of
protein was resolved on a 4–12% Bis-Tris gel (Bio-Rad, Hertford-
shire, UK) and transferred to nitrocellulose membranes. Membranes
were probed with antibodies diluted in 5% BSA as per Table 2,
before incubation with appropriate secondary horseradish peroxi-
dase-conjugated antibody. Blots were visualised with Immobilon
Western Chemiluminescence HRP Substrate (Merck Millipore, Hert-
fordshire, UK) and imaged with Syngene chemiluminescence imag-
ing system (SynGene, Cambridge, UK). Densitometry was
performed in ImageJ (Haywood et al, 2017).
Primary endothelial cell isolation
Primary endothelial cells (PECs) were isolated from lungs, as previ-
ously reported (Abbas et al, 2011; Watt et al, 2017). Briefly, lungs
were harvested, washed, finely minced and digested in Hanks’
balanced salt solution containing 0.18 units/ml collagenase (10 mg/
ml; Roche) for 45 min at 37°C. The digested tissue was filtered
through a 70-lm cell strainer and centrifuged at 400 g for 10 min.
The cell pellet was washed with PBS/0.5%BSA, centrifuged, re-
suspended in 1 ml PBS/0.5% and incubated with 1 × 106 CD146
antibody-coated beads (Miltenyi Biotec, 130-092-007) at 4°C for
30 min. Bead-bound endothelial cells were separated from non-
bead-bound cells using a magnet.
Microbiome analysis
Microbiome analysis was performed by UC Davis MMPC. Briefly,
frozen faecal samples were shipped on dry ice to UC Davis MMPC
and Host Microbe Systems Biology Core. Total DNA was extracted
using Mo-Bio (now Qiagen) Power Fecal Kit. Sample libraries were
prepared and analysed by barcoded amplicon sequencing(Anderson,
2001; Price et al, 2010; Lozupone et al, 2011; Quast et al, 2012;
Katoh & Standley, 2013; Mandal et al, 2015; Callahan et al, 2016;
Bolyen et al, 2019).
Quantification of white and brown adipose tissue vascularity
White adipose tissue (WAT) and brown adipose tissue (BAT)
(< 0.5 g) were harvested into cold 1% paraformaldehyde (PFA) and
allowed to fix for 2hrs at room temperature. Samples were incu-
bated overnight with Isolectin B4 Alexa Fluor 647 (I32450, Thermo
Fisher Scientific) and diluted 1:100 in 5% BSA in phosphate-
buffered saline (PBS) at 4°C. After washing with PBS, they were
incubated with HCS LipidTOX (H34475, Thermo Fisher Scientific)
diluted 1:200 in PBS for 20mins at room temperature. Whole tissue
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was then mounted onto slides beneath coverslips using a silicone
spacer (Grace bio-labs, 664113), with Prolong Gold (P36930,
Thermo Fisher Scientific). Slides were then imaged using laser scan-
ning confocal microscopy (LSM880, Zeiss), with 8 areas of each
sample imaged. Vascular density (the proportion of each image
stained with IB4) was measured using thresholding in ImageJ.
Histological assessment of adipocyte size, non-alcoholic fatty
liver disease and villi structure
Samples for histology were fixed in 4% PFA for at least 24 h and
then processed into paraffin blocks. 5-µm sections were taken and
collected onto 3-triethoxysilylpropylamine (TESPA) coated slides.
Table 2. Antibody details for protein expression.
Protein Supplier Code Secondary antibody
IGF1R (D23H3) Cell Signaling #9750 Anti Rabbit
IR (4B8) Cell Signaling #3025 Anti Rabbit
AKT Cell Signaling #9272 Anti Rabbit
p-AKT Ser473 Cell Signaling #9271 Anti Rabbit
eNOS Cell Signaling #9572 Anti Rabbit
p-eNOS Ser 1177 Cell Signaling #9570 Anti Rabbit
Table 1. Primer details for qPCR.
Gene Assay ID
IGF1R Insulin-like growth factor-1 receptor qHsaCED0044963
PIGR Polymeric immunoglobulin receptor qHsaCID0021506
MMP7 Matrix metallopeptidase 7 qHsaCED0044775
REG3G Regenerating family member 3
gamma
qHsaCED0004912




Insr Insulin receptor qMmuCID0018034





receptor, gamma, coactivator 1 alpha
qMmuCID0006032
Vegfa Vascular endothelial growth factor A qMmuCED0040260
Adipoq Adiponectin qMmuCID0023242
Lep Leptin qMmuCID0040177
Cyp7a1 Cytochrome P450, family 7, subfamily
a, polypeptide 1
qMmuCED0046994
Abcb11 ATP-binding cassette, subfamily B
(MDR/TAP), member 11
qMmuCID0015514
Mttp Microsomal triglyceride transfer
protein
qMmuCED0047210
Apob Apolipoprotein B qMmuCED0044141




Acsl3 Acyl-CoA synthetase long-chain family
member 3
qMmuCED0046845
Acsl5 Acyl-CoA synthetase long-chain family
member 5
qMmuCED0045475
Atl1 Atlastin GTPase 1 qMmuCED0044156
Cideb Cell death-inducing DFFA-like
effector b
qMmuCED0046272
Dgat1 Diacylglycerol O-acyltransferase 1 qMmuCID0021210




Plin2 Perilipin 2 qMmuCID0016776
Plin3 Perilipin 3 qMmuCID0005622
Aqp7 Aquaporin 7 qMmuCID0025269
Tlr3 Toll-like receptor 3 qMmuCID0005723




Nlrp6 NLR family pyrin domain containing 6 qMmuCED0048619




Ahr Aryl-hydrocarbon receptor qMmuCED0044800
Table 1 (continued)
Gene Assay ID
Nr1h4 Nuclear receptor subfamily 1, group
H, member 4
qMmuCID0014006
Vdr Vitamin D receptor qMmuCID0006555
Aldh1l1 qMmuCID0021991 qMmuCID0021991
Reg3g Regenerating family member 3
gamma
qMmuCED0040314
Retnlb Resistin-like beta qMmuCED0001569
Defb1 Defensin beta 1 qMmuCID0008786
Mmp7 Matrix metallopeptidase 7 qMmuCID0022398
F11r F11 receptor qMmuCID0006275
Myo1a Myosin IA qMmuCID0022137
Mgam Maltase-glucoamylase qMmuCID0022182
Pigr Polymeric immunoglobulin receptor qMmuCID0009049
Ifng Interferon gamma qMmuCID0006268
Il4 Interleukin 4 qMmuCID0006552
Muc2 Mucin 2 qMmuCID0019583
Muc3 Mucin 3 qMmuCID0023019
Flt1 FMS-like tyrosine kinase 1 qMmuCID0016762
Kdr Kinase insert domain protein receptor qMmuCID0005890
Flt4 FMS-like tyrosine kinase 4 qMmuCID0021117
Vegfc Vascular endothelial growth factor C qMmuCID0017182
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After drying, slides were stained with haematoxylin and eosin to
assess gross morphology  oil red o (ORO) for lipid staining. Slides
were imaged using an Olympus BX41 microscope at 10× and 20×
magnification.
For assessment of adipocyte size, three separate fields of view
for each sample were assessed. For each one, the average of 20
randomly selected independent cells measured using ImageJ.
For assessment of non-alcoholic fatty liver disease (NAFLD) in
sections of murine liver, a validated rodent NAFLD scoring system
was used (Liang et al, 2014), which takes into account micro- and
macro-steatosis, inflammation and hypertrophy. Each sample was
assessed by at least two blinded independent verifiers (NH, KB or
NW) and the average score per sample taken.
Flow cytometry
To isolate the stromal vascular fraction, epididymal fat pads were
harvested, washed, finely minced and digested in Hanks’ balanced
salt solution containing collagenase (1 mg/ml; Roche) for 45 min at
37°C. The digested tissue was agitated using a cannula and centri-
fuged at 1,000 rpm for 10 min. The upper lipid phase was removed
and the aqueous phase with pellet was filtered through a 70-µM cell
strainer and centrifuged at 1,000 rpm for 7 min. The pellet was re-
suspended in PBS containing 0.5% BSA (Sigma-Aldrich) and 2 mM
EDTA (Sigma-Aldrich) and was filter through a 30-µM cell strainer
and further centrifuged at 1,000 rpm for 7 min.
Cells from the stromal vascular fraction were washed and re-
suspended in PBS containing 0.5% BSA (Sigma-Aldrich) and 2 mM
EDTA (Sigma-Aldrich). Fc receptors were blocked with a CD16/32
antibody (Miltenyi Biotec, 130-092-575) for 10 min at 4°C. Samples
were then incubated with anti-CD45-VioBlue (Miltenyi Biotec, 130-
110-802), anti-CD11b-FITC (Miltenyi Biotec, 130-081-201), anti-
Ly6G-PE (Miltenyi Biotec, 130-107-913), anti-Ly6C-APC (eBio-
science, 17-5932-82) or anti-F4/80-APC (Miltenyi Biotec, 130-102-
379) for 10mins at 4°C, according to the manufacturer’s protocol.
Stained cells were washed in PBS containing 0.5% BSA and 2 mM
EDTA. Samples were analysed by flow cytometry (CytoFLEX S,
Beckman Coulter). Leukocytes were identified based on typical light
scatter properties, with further gating to define: CD45+ leukocytes,
CD45+CD11b+ myeloid cells, CD45+CD11b+Ly6GLy6Chi inflamma-
tory monocytes, CD45+CD11b+Ly6GLy6Clow reparative monocytes,
CD45+CD11b+Ly6GhiLy6Chi neutrophils and CD45+CD11b+F4/80+
macrophages. Data were scaled to cells/ml of blood or weight of
fat pad.
Pancreatic lipase activity
Tissue was harvested under terminal anaesthesia. 40 mg of pancreas
was homogenised and used in a lipase activity assay (Abcam,
ab102524).
Liver and plasma lipid measurements
100mg of tissue was weighed and homogenised in 1 ml of 5%
Igepal (I8896, Sigma) and heated to 80°C for 5 min, cooled and re-
heated again before centrifuging for 2 min. The supernatant was
used to measure, triglycerides, free fatty acids and cholesterol
(Abcam, ab65336, ab65341 and ab65359, respectively).
Conditioning media
Conditioned media experiments require a large number of EC, and
pulmonary EC provides an appropriate yield of cells to perform
these experiments. Therefore, when PECs reached confluency,
supplemented growth media was removed and replaced with basal
endothelial growth medium-MV2 for 24 h. Conditioned media was
then removed and used in further experiments as described.
Caco-2 cells
Caco-2 cells were purchased from Public Health England Culture
Collections (86010202). Pre-differentiated Caco-2 cells were main-
tained in 20% (v/v) FBS/MEME containing non-essential amino
acids, 0.292 g/l L-glutamine, 2.2 g/l sodium bicarbonate (Sigma-
Aldrich #M4655), supplemented with 1XAntibiotic Antimycotic
Solution (Sigma-Aldrich #A5955) and incubated at 37°C in 5% CO2.
Upon confluency, Caco-2 cell differentiation was initiated by seeding
on Transwell inserts. Differentiated Caco-2 cells were subjected to
boiled (5 min at 95°C) conditioned media stimulation at the basal
side for 24 h at 37°C in 5% CO2.
Data analysis
All data are shown as mean  standard error of mean (SEM) unless
stated, with individual mice presented as data points. All image
analysis was performed in ImageJ unless stated. Student unpaired t-
test was used for statistical analyses and performed with GraphPad
Prism software version 8 unless stated. For plasma concentration–
time profile experiments, area under the curve analyse was used
and performed with GraphPad Prims. For metabolic parameters
measured by indirect calorimetry, ANOVA testing was performed
using mass as a co-variant (ANCOVA testing) using calrapp.org.
P < 0.05 taken as statistically significant.
Data availability
No primary data sets have been generated and deposited.
Expanded View for this article is available online.
Acknowledgements
NJH was funded by British Heart Foundation Project grant (PG/18/82/34120).
CL was funded by a British Heart Foundation studentship (FS/19/59/34896).
MD was funded by British Heart Foundation Clinical Research Training
Fellowship (FS/18/44/33792). LDR was funded by a Diabetes UK RD Lawrence
Fellowship (16/0005382). RMC was funded by a British Heart Foundation Clin-
ical Intermediate Fellowship (FS/12/80/29821). MTK holds a British Heart
Foundation Chair in Cardiovascular and Diabetes Research (RG/15/7/31521).
NTW was funded by a British Heart Foundation project grant (PG/14/54/
30939). The Experimental and Preclinical Imaging Centre was co-funded by
the BHF (SI/14/1/30718). We would like to acknowledge the histology service
from the Division of Pathology and Data Analytics, Colorectal Pathology Trials,
University of Leeds, for sectioning and staining adipose and liver samples. We
would also like to acknowledge the Bio-imaging and Flow Cytometry Facility,
Faculty of Biological Sciences, University of Leeds, for acquiring images from
histology slides. We would also like to acknowledge the UC Davis MMPC
12 of 14 EMBO reports 22: e50767 | 2021 ª 2021 The Authors
EMBO reports Natalie J Haywood et al
services, whose research was supported by NIH grant U24-DK092993 (MMPC-
University of California Davis Microbiome and Host Response Core, RRID:SCR_
015361). MTK is the guarantor of this work and, as such, had full access to all
the data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Author contributions
NJH, KIB, NM, AS, NYY performed in vivo experiments. NJH, CL, KIB, CHO, NW,
MD, CGW, NTW performed ex vivo experiments. JK-P, IT, JHB, SS, JES, AM
performed in vivo imaging experiments. NJH, CL, performed cell culture experi-
ments. NJH and MTK wrote the manuscript. NJH, CL, KIB, NM, AS, CHO, NW,
MD, CGW, NTW, JKP, IT, JHB, SS, JES, NYY, LDR, DJB, PS, SBW, RMC, MTK
reviewed the manuscript. MTK, RMC, SBW, NYY, LDR, DJB, PS obtained funding.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Abbas A, Imrie H, Viswambharan H, Sukumar P, Rajwani A, Cubbon Rm, Gage
M, Smith J, Galloway S, Yuldeshava N et al (2011) The insulin-like growth
factor-1 receptor is a negative regulator of nitric oxide bioavailability and
insulin sensitivity in the endothelium. Diabetes 60: 2169 – 2178
Adams TE, Epa VC, Garrett TPJ, Ward CW (2000) Structure and function of
the type 1 insulin-like growth. Cell Mol Life Sci 57: 1050 – 1093
Amedei A, Morbidelli L (2019) Circulating metabolites originating from gut
microbiota control endothelial cell function. Molecules 24: 3992
Anderson MJ (2001) A new method for non-parametric multivariate analysis
of variance. Austral Ecol 26: 32 – 46
Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF,
Gordon JI (2004) The gut microbiota as an environmental factor that
regulates fat storage. Proc Natl Acad Sci 101: 15718 – 15723
Bettedi L, Foukas LC (2017) Growth factor, energy and nutrient sensing
signalling pathways in metabolic ageing. Biogerontology 18: 913 – 929
Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA,
Alexander H, Alm EJ, Arumugam M, Asnicar F et al (2019) Reproducible,
interactive, scalable and extensible microbiome data science using QIIME
2. Nat Biotechnol 37: 852 – 857
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP (2016)
DADA2: High-resolution sample inference from Illumina amplicon data. Nat
Methods 13: 581 – 583
Cani PD, de Vos WM (2017) Next-generation beneficial microbes: the case of
Akkermansia muciniphila. Front Microbiol 8: 1765
Castaner O, Goday A, Park Y-M, Lee S-H, Magkos F, Shiow S-ATE, Schröder H
(2018) The gut microbiome profile in obesity: a systematic review. Int J
Endocrinol 2018: 1 – 9
Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens J-F, Lobysheva
I, Plovier H, Essaghir A, Demoulin J-B et al (2018) Targeting the gut
microbiota with inulin-type fructans: preclinical demonstration of a novel
approach in the management of endothelial dysfunction. Gut 67: 271 – 283
Chan YK, Brar MS, Kirjavainen PV, Chen Y, Peng J, Li D, Leung FC-C, El-Nezami H
(2016) High fat diet induced atherosclerosis is accompanied with low
colonic bacterial diversity and altered abundances that correlates with
plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet
and its intervention with Lactobacillus rhamno. BMC Microbiol 16: 264
Chang C-S, Kao C-Y (2019) Current understanding of the gut microbiota
shaping mechanisms. J Biomed Sci 26: 59
Cintron-Colon R, Sanchez-Alavez M, Nguyen W, Mori S, Gonzalez-Rivera R,
Lien T, Bartfai T, A€ıd S, François J-C, Holzenberger M et al (2017) Insulin-
like growth factor 1 receptor regulates hypothermia during calorie
restriction. Proc Natl Acad Sci 114: 9731 – 9736
Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser
BD, Levenez F, Chilloux J, Hoyles L et al (2016) Akkermansia muciniphila and
improved metabolic health during a dietary intervention in obesity:
relationship with gut microbiome richness and ecology. Gut 65: 426 – 436
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S,
Falony G, Raes J, Maiter D, Delzenne NM et al (2019) Supplementation
with Akkermansia muciniphila in overweight and obese human volunteers:
a proof-of-concept exploratory study. Nat Med 25: 1096 – 1103
Derrien M, Vaughan EE, Plugge CM, de Vos WM (2004) Akkermansia
muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading
bacterium. Int J Syst Evol Microbiol 54: 1469 – 1476
Ding B-S, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V,
Kobayashi H, Shido K, Lyden D et al (2010) Inductive angiocrine signals from
sinusoidal endothelium are required for liver regeneration. Nature 468: 310– 315
Dong CX, Zhao W, Solomon C, Rowland KJ, Ackerley C, Robine S, Holzenberger
M, Gonska T, Brubaker PL (2014) The intestinal epithelial insulin-like
growth factor-1 receptor links glucagon-like peptide-2 action to gut
barrier function. Endocrinology 155: 370 – 379
Everard A, Belzer C, Geurts L, Ouwerkerk Jp, Druart C, Bindels Lb, Guiot Y,
Derrien M, Muccioli Gg, Delzenne Nm et al (2013) Cross-talk between
Akkermansia muciniphila and intestinal epithelium controls diet-induced
obesity. Proc Natl Acad Sci 110: 9066 – 9071
Fujimoto M, Kawashima Sonoyama Y, Hamajima N, Hamajima T, Kumura Y,
Miyahara N, Nishimura R, Adachi K, Nanba E, Hanaki K et al (2015)
Heterozygous nonsense mutations near the C-terminal region of IGF1R in
two patients with small-for-gestational-age-related short stature. Clin
Endocrinol 83: 834 – 841
Gallagher EJ, Leroith D (2015) Obesity and diabetes: the increased risk of cancer
and cancer related mortality epidemiology. Physiol Rev 95: 727 – 748
Garcia M, Kakarieka E, Johnson MC, Jose J (2014) IGF-IR signal transduction
protein content and its activation by IGF-I in human placentas:
relationship with gestational age and birth weight. PLoS One 9: 1 – 7
Garrett WS (2020) Immune recognition of microbial metabolites. Nat Rev
Immunol 20: 91 – 92
Griffin C, Lanzetta N, Eter L, Singer K (2016) Sexually dimorphic myeloid
inflammatory and metabolic responses to diet-induced obesity. Am J
Physiol Integr Comp Physiol 311: R211 –R216
Guariguata L, Whiting Dr, Hambleton I, Beagley J, Linnenkamp U, Shaw Je
(2013) Global estimates of diabetes prevalence for 2013 and projections
for 2035. Diabetes Res Clin Pract 103: 137 – 149
Haywood NJ, Cordell PA, Tang KY, Makova N, Yuldasheva NY, Imrie H,
Viswambharan H, Bruns AF, Cubbon RM, Kearney MT et al (2017) Insulin-
like growth factor binding protein 1 could improve glucose regulation and
insulin sensitivity through its RGD domain. Diabetes 66: 287 – 299
Imrie H, Viswambharan H, Sukumar P, Abbas A, Cubbon Rm, Yuldasheva N,
Gage M, Smith J, Galloway S, Skromna A et al (2012) Novel role of the
IGF-1 receptor in endothelial function and repair: studies in endothelium-
targeted IGF-1 receptor transgenic mice. Diabetes 61: 2359 – 2368
Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding
proteins: biological actions. Endocr Rev 16: 3 – 34
Juanes M, Guercio G, Marino R, Berensztein E, Diana M, Ciaccio M, Gil S,
Bailez M, Rivarola MA, Belgorosky A (2015) Three novel IGF1R mutations
in microcephalic patients with prenatal and postnatal growth impairment.
Clin Endocrinol 82: 704 – 711
ª 2021 The Authors EMBO reports 22: e50767 | 2021 13 of 14
Natalie J Haywood et al EMBO reports
Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D,
B€ackhed F, Nielsen J (2012) Symptomatic atherosclerosis is associated
with an altered gut metagenome. Nat Commun 3: 1245
Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software
version 7: improvements in performance and usability. Mol Biol Evol 30:
772 – 780
Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG (2016) Role of gut
microbiota in the aetiology of obesity: proposed mechanisms and review
of the literature. J Obes 2016: 1 – 27
Kivel€a R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H,
Takakura N, Peng X, Sawyer DB, Elenius K et al (2019) Endothelial cells
regulate physiological cardiomyocyte growth via VEGFR2-mediated
paracrine signaling. Circulation 139: 2570 – 2584
Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, Behre Cj, Knight R,
Fagerberg B, Ley Re et al (2011) Human oral, gut, and plaque microbiota
in patients with atherosclerosis. Proc Natl Acad Sci 108: 4592 – 4598
Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A,
Roos KP, Iruela-Arispe ML (2007) Autocrine VEGF signaling is required for
vascular homeostasis. Cell 130: 691 – 703
Leslie JL, Annex BH (2018) The microbiome and endothelial function. Circ Res
123: 1015 – 1016
Li Z, Chalazonitis A, Huang Y-y, Mann Jj, Margolis Kg, Yang Qm, Kim Do, Cote
F, Mallet J, Gershon Md (2011) Essential roles of enteric neuronal
serotonin in gastrointestinal motility and the development/survival of
enteric dopaminergic neurons. J Neurosci 31: 8998 – 9009
Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM,
Kleemann R, van den Hoek AM (2014) Establishment of a general NAFLD
scoring system for rodent models and comparison to human liver
pathology. PLoS One 9: 1 – 17
Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R (2011) UniFrac: an
effective distance metric for microbial community comparison. ISME J 5:
169 – 172
Lynch SV, Pedersen O (2016) The human intestinal microbiome in health and
disease. N Engl J Med 375: 2369 – 2379
Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD
(2015) Analysis of composition of microbiomes: a novel method for
studying microbial composition. Microb Ecol Heal Dis 26: 27663
Mughal RS, Bridge K, Buza I, Slaaby R, Worm J, Klitgaard-Povlsen G, Hvid H,
Schiødt M, Cubbon R, Yuldasheva N et al (2019) Effects of obesity on
insulin: insulin-like growth factor 1 hybrid receptor expression and Akt
phosphorylation in conduit and resistance arteries. Diabetes Vasc Dis Res
16: 160 – 170
Natividad JM, Lamas B, Pham HP, Michel M-L, Rainteau D, Bridonneau C, da
Costa G, van Hylckama Vlieg J, Sovran B, Chamignon C et al (2018)
Bilophila wadsworthia aggravates high fat diet induced metabolic
dysfunctions in mice. Nat Commun 9: 2802
Nuenen MHMC, Ligt RAF, Doornbos RP, Woude JCJ, Kuipers EJ, Venema K (2005)
The influence of microbial metabolites on human intestinal epithelial cells
and macrophages in vitro. FEMS Immunol Med Microbiol 45: 183 – 189
Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF, Stanton C
(2016) Gut microbiota, obesity and diabetes. Postgrad Med J 92: 286 – 300
Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J,
Ottman N, Duparc T, Lichtenstein L et al (2017) A purified membrane
protein from Akkermansia muciniphila or the pasteurized bacterium
improves metabolism in obese and diabetic mice. Nat Med 23: 107 – 113
Price MN, Dehal PS, Arkin AP (2010) FastTree 2 – approximately maximum-
likelihood trees for large alignments. PLoS One 5: e9490
Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner
FO (2012) The SILVA ribosomal RNA gene database project: improved data
processing and web-based tools. Nucleic Acids Res 41: D590 –D596
Roberts L, Boström P, O’Sullivan J, Schinzel R, Lewis G, Dejam A, Lee Y-K,
Palma M, Calhoun S, Georgiadi A et al (2014) b-aminoisobutyric acid
induces browning of white fat and hepatic b-oxidation and is inversely
correlated with cardiometabolic risk factors. Cell Metab 19: 96 – 108
Rodrigues RR, Greer RL, Dong X, DSouza KN, Gurung M, Wu JY, Morgun A,
Shulzhenko N (2017) Antibiotic-induced alterations in gut microbiota are
associated with changes in glucose metabolism in healthy mice. Front
Microbiol 8: 2306
Schieber AMP, Lee YM, Chang MW, Leblanc M, Collins B, Downes M, Evans
RM, Ayres JS (2015) Disease tolerance mediated by microbiome E. coli
involves inflammasome and IGF-1 signaling. Science 350: 558 – 563
Shin JH, Seeley RJ (2019) Reg3 proteins as gut hormones? Endocrinology 160:
1506 – 1514
Stubbins RE, Holcomb VB, Hong J, Nu~nez NP (2012) Estrogen modulates
abdominal adiposity and protects female mice from obesity and impaired
glucose tolerance. Eur J Nutr 51: 861 – 870
Tang X, Miao Y, Luo Y, Sriram K, Qi Z, Lin F-M, Gu Y, Lai C-H, Hsu C-Y,
Peterson KL et al (2020) Suppression of endothelial AGO1 promotes
adipose tissue browning and improves metabolic dysfunction. Circulation
142: 365 – 379
Tsao J, Jiang Y (2013) Hierarchical IDEAL: fast, robust, and multiresolution
separation of multiple chemical species from multiple echo times.
Hierarchical IDEAL Fast, Robust, Multiresolution Sep Mult Chem Species from
Mult Echo Times 159: 155 – 159
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006)
An obesity-associated gut microbiome with increased capacity for energy
harvest. Nature 444: 1027 – 1031
Vrieze A, Van Nood E, Holleman F, Saloj€arvi J, Kootte RS, Bartelsman JFWM,
Dallinga–Thie GM, Ackermans MT, Serlie MJ, Oozeer R et al (2012) Transfer
of intestinal microbiota from lean donors increases insulin sensitivity in
individuals with metabolic syndrome. Gastroenterology 143: 913 – 916.e7
Watt NT, Gage MC, Patel PA, Viswambharan H, Sukumar P, Galloway S,
Yuldasheva NY, Imrie H, Walker AMN, Griffin KJ et al (2017) Endothelial
SHIP2 suppresses Nox2 NADPH oxidase-dependent vascular oxidative
stress, endothelial dysfunction, and systemic insulin resistance. Diabetes
66: 2808 – 2821
Woods K, Camacho-Hubner C, Savage M, Clark A (1996) Intrauterine
growth retardation and postnatal growth failure associated with
deletion of the insulin - like growth factor I gene. N Engl J Med 335:
1363 – 1367
Yan J, Herzog JW, Tsang K, Brennan CA, Bower MA, Garrett WS, Sartor BR,
Aliprantis AO, Charles JF (2016) Gut microbiota induce IGF-1 and promote
bone formation and growth. Proc Natl Acad Sci 113: E7554 – E7563
Yki-J€arvinen H (2014) Non-alcoholic fatty liver disease as a cause and a
consequence of metabolic syndrome. Lancet Diabet Endocrinol 2: 901 – 910
Zhang F, Zarkada G, Han J, Li J, Dubrac A, Ola R, Genet G, Boye K, Michon P,
K€unzel SE et al (2018) Lacteal junction zippering protects against diet-
induced obesity. Science 361: 599 – 603
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
EMBO reports Natalie J Haywood et al
14 of 14 EMBO reports 22: e50767 | 2021 ª 2021 The Authors
